Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

Venetoclax, an FDA-approved Bcl-2 selective inhibitor for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia (AML), is tolerated well in elderly patients with AML and has good overall response rates; however, resistance remains a concern. In this study, we show that targeting C...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Signal transduction and targeted therapy 2020-02, Vol.5 (1), p.17-17, Article 17
Hauptverfasser:	Luedtke, Daniel A., Su, Yongwei, Ma, Jun, Li, Xinyu, Buck, Steven A., Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Lin, Hai, Taub, Jeffrey W., Ge, Yubin
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/153 631/67/1990 Cancer Research Cell Biology Cell death Internal Medicine Leukemia Medicine Medicine & Public Health Oncology Pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!